Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CES2 | O00748 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29240939 | 0.83 | L3MBTL1 (0.44) | CES1ALDH1A1CES2TSHRDAO | |
| SCHEMBL27552924 | 0.79 | CES1 (0.52) | CES1ALDH1A1CES2TSHRDAO | |
| SCHEMBL28913988 | 0.78 | ALDH1A1 (0.43) | CES1ALDH1A1CES2TSHRNAPRT | |
| SCHEMBL29171473 | 0.78 | LMNA (0.50) | CES2MAPK1HIF1AMAPTCYP3A4 | |
| Benzophenone SCHEMBL11550529 | 0.77 | ALDH1A1 (0.74) | CES1ALDH1A1CES2TSHRDAO | |
| SCHEMBL6844400 | 0.77 | CES1 (0.50) | CES1ALDH1A1CES2TSHRDAO | |
| SCHEMBL1728427 | 0.77 | CES1 (0.50) | CES1ALDH1A1CES2TSHRDAO | |
| SCHEMBL9357017 | 0.77 | ALDH1A1 (0.46) | CES1ALDH1A1CES2TSHRDAO | |
| Benzoic Acid SCHEMBL6130967 | 0.77 | TSHR (0.74) | CES1ALDH1A1CES2TSHRDAO | |
| SCHEMBL9755055 | 0.77 | ALDH1A1 (0.46) | CES1ALDH1A1CES2TSHRDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | disclosed |
| CN-101511359-B | Benzotriazole kinase modulators | HOFFMANN LA ROCHE | 2012-09-05 | — | — | CN | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| CN-101511359-A | Benzotriazole kinase modulators | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2066319-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| WO-2008028860-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
| WO-2002076951-A1 | 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE THEREOF AS CYCLOOXYGENASE INHIBITORS | BEIERSDORF AG (DE) | 2002-10-03 | — | — | WO | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| CN-1186514-A | Process for controlling sialylation of protein produced by mammalian cell culture | GENENTECH INC (US) | 1998-07-01 | — | — | CN | disclosed |
| EP-0271780-A2 | Substituted 1-benzylsulfonyl-3-heteroaryl(thio) urea | BAYER AG (DE) | 1988-06-22 | — | — | EP | disclosed |
| US-4709047-A | CATALYSTS FOR CROSSLINKING OF UNSATURATED IMIDES | CIBA-GEIGY CORPORATION (US) | 1987-11-24 | — | — | US | disclosed |
| EP-0001797-B1 | PROCESS FOR THE ISOLATION OF CEPHALOSPORIN C, ITS SALTS AND ITS DERIVATIVES, FROM CULTURE MEDIA AND SOLUTIONS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-06-17 | — | — | EP | disclosed |
| US-4204058-A | Process for obtaining cephalosporin C and the salts and derivatives thereof from culture filtrates or culture solutions | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-05-20 | — | — | US | disclosed |
| EP-0001797-A1 | Process for the isolation of cephalosporin C, its salts and its derivatives, from culture media and solutions | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | CES1 3579/4885ALDH1A1 2989/4885CES2 4072/4885 |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | CES1 1327/4885ALDH1A1 1612/4885CES2 2984/4885 |
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | CES1 3556/4885ALDH1A1 2630/4885CES2 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.